Eli Lilly to use GLP-1 windfall to fund M&A and diversify pipeline
Jacob Van Naarden is busy. In addition to running Eli Lilly‘s oncology business, he’s now responsible for finding the drugmaker’s next opportunities as head of business development. And Lilly, now the world’s largest pharmaceutical company, is hungrier than ever for deals. “The company’s financial strength right now, driven mostly by the weight loss business, is…